SOLA Biosciences

5 articles about SOLA Biosciences

• SOLA Biosciences Presents Preclinical Proof-of-Concept Data for SOL-257, a Gene Therapy Targeting Misfolded TDP-43 in ALS, at Neuroscience 2023 and ALS One Symposium

  11/9/2023

  As a pioneer in innovative chaperone technology, SOLA Biosciences Inc. will present its compelling preclinical proof-of-concept data for SOL-257, a targeted gene therapy for misfolded TDP-43 in Amyotrophic Lateral Sclerosis, at Neuroscience 2023 in Washington, D.C. on November 15 and the ALS One Symposium on November 17.

• SOLA Biosciences Presented Positive ALS Animal Efficacy Data of SOL-257 at the 1st Annual MDA Insight in Research Investor Summit for Neuromuscular Disease

  4/29/2021

  SOLA Biosciences, LLC, today announced positive preclinical data in mice from a study designed to evaluate the efficacy of SOL-257, an innovative gene therapy candidate selectively targeting pathogenic TDP-43, which is found in approximately 97% of ALS patients.

• SOLA Biosciences Announces Distribution Agreement with Cosmo Bio Co., Ltd

  9/27/2016

• SOLA Biosciences Makes Cooperative Research And Manufacturing Agreement With SBH Sciences, Inc.

  5/27/2016

• SOLA Biosciences Announces New Website Launch

  5/18/2016